Esketamine Combined With PRF of DRG for Acute/Subacute Zoster-associated Pain
Esketamine Intravenous Infusion Combined With Pulsed Radiofrequency of Dorsal Root Ganglion for Acute and Subacute Herpes Zoster Neuralgia: A Randomized Controlled Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Fang Luo
- Phone Number: +86 13611326978
- Email: 13611326978@163.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100070
- Beijing Tiantan Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Ages more than 18 years;
- Patients with onset of herpes zoster (HZ) rash less than 90 days;
- HZ affected the spinal nerves (cervical/thoracic/lumbar nerve);
- Having an average pain score of at least 4 on a Numeric Rating Scale (NRS, 0 = no pain, 10= worst possible pain);
- Planned to perform CT-guided PRF treatment of the dorsal root ganglion(DRG).
Exclusion Criteria:
- Obstructive sleep apnoea syndrome;
- Those who receive other more invasive treatments, such as radiofrequency thermocoagulation (RFT) of DRG.
- A history of systemic immune diseases, organ transplantation, or cancers;
- A history of severe cardiopulmonary, hepatic, renal dysfunction or coagulation function disorder;
- A history of schizophrenia, epilepsy, or myasthenia gravis, delirium;
- Comorbid hyperthyroidism or phaeochromocytoma;
- Recent history of drug abuse;
- Having contraindications to esketamine;
- Communication difficulties.
- Women who are preparing for pregnancy, in the pregnancy or lactation period.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Esketamine group
Esketamine+ PRF group
|
in addition to receiving the combination of PRF of DRG and standardized drug treatment, patients will also undergo a single intravenous infusion of esketamine.
Other Names:
|
|
Active Comparator: control group
PRF group
|
In the control group, patients will receive PRF+standardized drug treatment.
Pulsed radiofrequency (PRF) will be performed on DRG by an designated physician in each participating center.
They will be treated with PRF (PMG-230, Baylis Medical Inc.) using a 21-gauge sterilized radiofrequency needle (a 10-cm trocar with a 5-mm active tip, PMF-21-100-5, Baylis Medical Inc.), which are carefully inserted until the needle tip reaches the upper edge of the intervertebral foramen.
The parameters of PRF treatment will be set at 42 ℃, 2 Hz with 20 milliseconds current.
The standardized drug treatment will include antiviral therapy, anticonvulsant treatment, three-step analgesic therapy
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
the NRS score at 1 month after treatment.
Time Frame: 1-month period
|
The Numeric Rating Scale (NRS) score is a way to quantify the degree of subjective feelings such as pain using numbers.
Generally, 0 represents no pain, and 10 represents the most severe pain.A higher score indicates more severe pain
|
1-month period
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
the 12-item Short-Form Health Survey (SF-12) score
Time Frame: at 1 week, 2 weeks, 1 month, 2 months, 3 months after treatment
|
Quality of life (QoL) assessed by the SF-12 score (range 0-100, with higher scores indicating better health status)
|
at 1 week, 2 weeks, 1 month, 2 months, 3 months after treatment
|
|
the Pittsburgh Sleep Quality Index (PSQI) score
Time Frame: at 1 week, 2 weeks, 1 month, 2 months, 3 months after treatment
|
Sleep quality measured by PSQI score (range 0-21, with higher scores indicating poorer sleep quality).
|
at 1 week, 2 weeks, 1 month, 2 months, 3 months after treatment
|
|
The Patient Global Impression of Change scale (PGIC)
Time Frame: at 1 week, 2 weeks, 1 month, 2 months, 3 months after treatment
|
The proportion of patients with a response of "no change", "minimally improved", "much improved" or "very much improved" on PGIC
|
at 1 week, 2 weeks, 1 month, 2 months, 3 months after treatment
|
|
Analgesics consumption
Time Frame: at 1 week, 2 weeks, 1 month, 2 months, 3 months after treatment
|
the type of analgesics and analgesics consumption
|
at 1 week, 2 weeks, 1 month, 2 months, 3 months after treatment
|
|
success rate
Time Frame: at 1 week, 2 weeks, 1 month, 2 months, 3 months after treatment
|
The success rate is defined as more than a 50% reduction in NRS-11 score
|
at 1 week, 2 weeks, 1 month, 2 months, 3 months after treatment
|
|
the NRS score after treatment
Time Frame: at 1 week, 2 weeks, 2 months, 3 months after treatment
|
Generally, 0 represents no pain, and 10 represents the most severe pain.A higher score indicates more severe pain.
|
at 1 week, 2 weeks, 2 months, 3 months after treatment
|
|
Safety assessments
Time Frame: at 0 day, 1 day, 1 week, 2 weeks,1 month, 2 months, 3 months
|
intraoperative complications, PRF-related complications, esketamine-related complications
|
at 0 day, 1 day, 1 week, 2 weeks,1 month, 2 months, 3 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- KY-2024-332-02-04
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.